Ignite Creation Date:
2025-12-24 @ 10:50 PM
Ignite Modification Date:
2025-12-29 @ 3:35 AM
Study NCT ID:
NCT02249169
Status:
COMPLETED
Last Update Posted:
2022-08-17
First Post:
2014-09-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome
Sponsor:
Mayo Clinic
Organization:
Study Overview
Official Title:
Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome
Status:
COMPLETED
Status Verified Date:
2022-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This longitudinal study is being done to understand mechanisms underlying development of irritable bowel syndrome (IBS) and the role of the gut bacteria in development of symptoms. This information will be used to determine whether temporal changes in gut microbial taxonomy and metabolism are associated with changes in symptom severity in IBS, and if targeted dietary interventions, including prebiotics, can reverse or moderate these changes.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: